Loading…

Metabolic defects shared by Alzheimer's disease and diabetes: A focus on mitochondria

Type 2 diabetes (T2D) and Alzheimer's disease (AD) are two global epidemics that share several metabolic defects, such as insulin resistance, impaired glucose metabolism, and mitochondrial defects. Importantly, strong evidence demonstrates that T2D significantly increases the risk of cognitive...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in neurobiology 2023-04, Vol.79, p.102694-102694, Article 102694
Main Authors: Carvalho, Cristina, Moreira, Paula I.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Type 2 diabetes (T2D) and Alzheimer's disease (AD) are two global epidemics that share several metabolic defects, such as insulin resistance, impaired glucose metabolism, and mitochondrial defects. Importantly, strong evidence demonstrates that T2D significantly increases the risk of cognitive decline and dementia, particularly AD. Here, we provide an overview of the metabolic defects that characterize and link both pathologies putting the focus on mitochondria. The biomarker potential of mitochondrial components and the therapeutic potential of some drugs that target and modulate mitochondria are also briefly discussed. •Type 2 diabetes (T2D) is an important risk factor for Alzheimer's disease (AD).•Mitochondrial dysfunction is a shared feature between T2D and AD.•Mitochondrial components found in peripheral blood are potential biomarkers of neurodegeneration.•Mitochondria-targeted drugs have the potential to treat neurodegenerative conditions.
ISSN:0959-4388
1873-6882
DOI:10.1016/j.conb.2023.102694